Provided by Tiger Trade Technology Pte. Ltd.

Oncolytics Biotech Inc

0.8431
+0.04145.16%
Post-market: 0.8300-0.0131-1.55%19:58 EDT
Volume:544.36K
Turnover:447.50K
Market Cap:107.50M
PE:-2.62
High:0.8492
Open:0.8000
Low:0.8000
Close:0.8017
52wk High:1.51
52wk Low:0.7301
Shares:127.51M
Float Shares:122.97M
Volume Ratio:0.73
T/O Rate:0.44%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3215
EPS(LYR):-0.3000
ROE:-10187.64%
ROA:-211.24%
PB:-17.43
PE(LYR):-2.81

Loading ...

Oncolytics Biotech Inc. : H.c. Wainwright Cuts Target Price to $5 from $10

THOMSON REUTERS
·
Aug 19

U.S. Research Roundup-Cogent Communications, Dollar Tree, Home Depot

Reuters
·
Aug 19

Oncolytics aligns with FDA on path for REO 033 expansion study

TIPRANKS
·
Aug 18

Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line Ras-Mutant Mss Colorectal Cancer

THOMSON REUTERS
·
Aug 18

Oncolytics Biotech - Receives FDA Feedback on Pivotal Part B Expansion of Reo 033

THOMSON REUTERS
·
Aug 18

Oncolytics Says FDA Aligns on Pivotal Expansion Path for REO 033 Colorectal Cancer Trial

Reuters
·
Aug 18

Oncolytics Net Loss Widens to $9.44 Million in Q2 2026; R&D Expenses More than Doubled to $4.26 Million

Reuters
·
Aug 13

Oncolytics Biotech Gets NASDAQ Notice for Failing $1 Minimum Bid Price Rule

Reuters
·
Jul 25

Oncolytics Biotech Announces Press Release Available

Reuters
·
Jul 20

Oncolytics Biotech Wins FDA Fast Track Status for Pelareorep in Second-line Anal Cancer

Reuters
·
Jul 20

Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-line and Later Anal Cancer

THOMSON REUTERS
·
Jul 20

Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (STOK) and Oncolytics Biotech (ONCY)

TIPRANKS
·
Jul 14

Oncolytics Biotech to Meet FDA on Registrational Pathway for REO 033 Colorectal Cancer Trial

Reuters
·
Jul 13

Oncolytics Biotech - Half of Reo 33 Clinical Sites to be Activated This Month; over 20 Patients Pre-identified

THOMSON REUTERS
·
Jul 13

Oncolytics Biotech - to Hold Type D FDA Meeting on Reo 33 Registration Pathway

THOMSON REUTERS
·
Jul 13

Oncolytics Biotech - Initial Reo 33 Part a Tumor Response Update Expected by Year-end 2026; Part B Enrollment May Begin Q1 2027

THOMSON REUTERS
·
Jul 13

Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized Ras-mutant Mss Colorectal Cancer Trial

THOMSON REUTERS
·
Jul 13

Oncolytics Biotech - Remaining Reo 33 Sites to be Activated by End of August for Accelerated Enrollment in H2 2026

THOMSON REUTERS
·
Jul 13

Oncolytics Biotech Swaps Auditor Ernst & Young for Baker Tilly

Reuters
·
Jul 09

Sector Update: Healthcare Stocks Advance in Afternoon Trading

MT Newswires Live
·
Jun 17